Evaluation of the effect of medroxyprogesterone acetate on bone marrow progenitor cells

P. Pedrazzoli, G. Bacciocchi, G. Antonio Da Prada, P. Preti, L. Pavesi, G. Poggi, Franco Locatelli, V. Rosti, G. Robustelli Della Guna

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Various clinical studies have demonstrated that high-dose medroxyprogesterone acetate (HD-MPA) can reduce hematologic toxicity in patients receiving chemotherapy for advanced solid tumors. The underlying mechanism(s) of this action is still unknown. A direct effect of MPA on hemopoietic cells has been postulated, but in vitro studies have given contradictory results. To clarify the biologic activity of MPA on hemopoiesis we have evaluated in vitro growth of pluripotent and committed progenitor cells from bone marrow cells which were preincubated in vitro with various doses of MPA and subsequently treated with or without the S-phase-specific drug arabinoside-cytosine (Ara-C). Four healthy subjects and 8 patients with advanced stage solid tumors with no bone marrow involvement were studied. In our experimental model we did not observe any effect of MPA on Ara-C killing of progenitor cells from either bone marrow mononuclear cells or bone marrow mononuclear cells depleted of T-lymphocytes and adherent cells. These results suggest that MPA does not act directly (or indirectly through the production of cytokines by T-lymphocytes and/or monocytes and macrophages) on bone marrow progenitors. In addition, the supposed mechanism of rendering stem cells less susceptible to the insult of cytotoxic drugs by lowering the number of progenitors in the S-phase has been ruled out by cell kinetic studies.
Lingua originaleEnglish
pagine (da-a)399-402
Numero di pagine4
Stato di pubblicazionePubblicato - 1991


  • Bone Marrow / drug effects


Entra nei temi di ricerca di 'Evaluation of the effect of medroxyprogesterone acetate on bone marrow progenitor cells'. Insieme formano una fingerprint unica.

Cita questo